Oncodetect, Inc. 

In quest for superior diagnosis and treatment

 

Innovative diagnosis and therapeutic strategies

 
HomeDevelopment of recombinant p21 protein as a viable therapy for AIDSINVESTORS NEEDEDSCIENCE CONSULTANTNEWSExecutive SummaryBreast Cancer testp21 drug development

oncod.jpg

Mission:  OncoDetect Inc. is a Bio-pharmaceutical company dedicated to extending and enhancing the lives of cancer and transplant patients.Company Stage:  OncoDetect is built on the research of Dr. Ashwani Khanna.  The company is in the process of securing intellectual property rights to key innovations and proceeding with feasibility studies in several promising areas.  Development Areas:·        Molecular Diagnostic assay for breast cancer detection and monitoring·        Use of p21 protein to suppress abnormal cell proliferation specifically to prevent organ transplant rejection, cancer progression and atherosclerosis·        Use of anti-TGF-b antibody to limit kidney damage in organ transplant recipients.·        Diagnostic assay to monitor transplant rejection and kidney damage in organ transplant recipients.Principle:

·        Ashwani Khanna, PhD, President, Chief Scientific Officer

443-896-4234

akhanna@oncodetect.com